Capstone Asset Management Co. decreased its stake in Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) by 0.8% during the third quarter, Holdings Channel reports. The institutional investor owned 9,562 shares of the biopharmaceutical company’s stock after selling 79 shares during the period. Capstone Asset Management Co.’s holdings in Regeneron Pharmaceuticals were worth $3,844,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $207,000. A.R.T. Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $1,185,000. Squarepoint Ops LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $1,703,000. BlueMountain Capital Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 92.5% in the first quarter. BlueMountain Capital Management LLC now owns 1,885 shares of the biopharmaceutical company’s stock valued at $679,000 after buying an additional 906 shares during the last quarter. Finally, New England Research & Management Inc. increased its stake in shares of Regeneron Pharmaceuticals by 17.4% in the second quarter. New England Research & Management Inc. now owns 1,145 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 170 shares during the last quarter. Institutional investors and hedge funds own 68.26% of the company’s stock.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded down 0.80% during midday trading on Tuesday, hitting $387.26. 752,140 shares of the stock traded hands. The stock has a 50-day moving average of $381.52 and a 200-day moving average of $389.62. The company has a market cap of $40.60 billion, a price-to-earnings ratio of 56.50 and a beta of 1.79. Regeneron Pharmaceuticals Inc. has a 52-week low of $325.35 and a 52-week high of $563.79.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, November 4th. The biopharmaceutical company reported $3.13 earnings per share for the quarter, beating analysts’ consensus estimates of $2.73 by $0.40. Regeneron Pharmaceuticals had a net margin of 16.52% and a return on equity of 21.51%. The business earned $1.22 billion during the quarter, compared to analysts’ expectations of $1.29 billion. During the same period last year, the business earned $3.47 earnings per share. The business’s revenue for the quarter was up 7.3% on a year-over-year basis. On average, equities analysts predict that Regeneron Pharmaceuticals Inc. will post $11.73 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Capstone Asset Management Co. Sells 79 Shares of Regeneron Pharmaceuticals Inc. (REGN)” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at http://www.dailypolitical.com/2016/11/29/capstone-asset-management-co-sells-79-shares-of-regeneron-pharmaceuticals-inc-regn.html.

A number of analysts have issued reports on the stock. Cowen and Company reiterated a “hold” rating and issued a $430.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. Roth Capital reiterated a “buy” rating and issued a $520.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, September 23rd. BTIG Research reiterated a “neutral” rating on shares of Regeneron Pharmaceuticals in a report on Thursday, November 17th. Piper Jaffray Cos. set a $447.00 price target on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, October 13th. Finally, Canaccord Genuity set a $450.00 price target on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Sunday, November 6th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $468.87.

In other news, Director Joseph L. Goldstein sold 2,125 shares of the firm’s stock in a transaction that occurred on Monday, November 14th. The shares were sold at an average price of $450.00, for a total value of $956,250.00. Following the completion of the transaction, the director now owns 15,125 shares of the company’s stock, valued at $6,806,250. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Arthur F. Ryan sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $429.34, for a total transaction of $858,680.00. Following the completion of the transaction, the director now directly owns 36,500 shares of the company’s stock, valued at approximately $15,670,910. The disclosure for this sale can be found here. Company insiders own 10.40% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN).

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.